Avagacestat

Drug Profile

Avagacestat

Alternative Names: Amyloid beta modulator - Bristol-Myers Squibb; Aβ modulator - Bristol-Myers Squibb; BMS-708163

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antidementias
  • Mechanism of Action Amyloid precursor protein secretase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 05 Dec 2012 Bristol-Myers Squibb discontinues development for Alzheimer's disease because of lack of efficacy at phase II
  • 30 Nov 2012 Discontinued - Phase-I for Alzheimer's disease in India (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top